Peptimmune, Inc. Garners $8,200,000 Series D Financing Round
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=e0e7bbed-5567-43e6-875f-7113717fdfe4&Preview=1 -
Date
1/17/2008 -
Company Name
Peptimmune, Inc. -
Mailing Address
64 Sidney Street Cambridge, MA 02139 -
Company Description
Peptimmune is a clinical stage biotechnology company that is utilizing both novel and proven technologies to improve the therapeutic management of chronic autoimmune and metabolic disorders. -
Website
http://www.peptimmune.com -
Transaction Type
Venture Equity -
Transaction Amount
$8,200,000 -
Transaction Round
Series D -
Proceeds Purposes
Proceeds of the $8.2 million second tranche are expected to be used mainly to advance clinical development of Peptimmune’s multiple sclerosis treatment, PI-2301. More than 400,000 Americans have multiple sclerosis (MS), and worldwide MS may affect over 2.5 million individuals, according to the company. -
M&A Terms
-
Venture Investor
New Enterprise Associates -
Venture Investor
MPM Capital -
Venture Investor
Hunt Ventures -
Venture Investor
Silicon Valley Bank
